Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 30S ribosomal initiation complex interface is a highly coordinated molecular assembly essential for the start of protein synthesis in bacteria (Gualerzi & Pon, 2015) [1]. It involves the interaction between the 30S small ribosomal subunit, messenger RNA, and three specific initiation factors: IF1, IF2, and IF3. This interface ensures that the initiator transfer RNA (fMet-tRNA) is correctly positioned at the start codon within the ribosomal P-site, a process critical for maintaining the translational reading frame. Because the architecture and regulation of bacterial initiation differ significantly from the eukaryotic process, this interface represents a selective target for antimicrobial agents (Wilson, 2014) [4]. Antibiotics such as kasugamycin and GE81112 exert their effects by binding to this interface, thereby obstructing the binding of initiation factors or the recruitment of the initiator tRNA (Schluenzen et al., 2006; Brandi et al., 2006) [2, 3]. Such interference prevents the subsequent docking of the 50S large ribosomal subunit, effectively halting the formation of the functional 70S ribosome and stopping bacterial growth. Consequently, this target is a focal point for developing new classes of antibiotics to address the rising challenge of multi-drug resistant infections.
Inhibition of the assembly of the 30S initiation complex or prevention of its transition to the 70S initiation complex by interfering with initiation factor binding or tRNA positioning.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 30S ribosomal initiation complex interface (30S IC interface).